Takeda to acquire exclusive worldwide (ex-China) license of HUTCHMED's Fruquintinib Ruchika Sharma26 Jan 2023 3:30 PM ISTUnder the terms of the agreement, Takeda will receive an exclusive worldwide license to develop and commercialize fruquintinib in all indications and...
Takeda to acquire Oral Allosteric TYK2 Inhibitor NDI-034858 from Nimbus Therapeutics Ruchika Sharma14 Dec 2022 11:01 AM ISTJapan: Takeda has announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric...
Takeda Dengue Tetravalent Vaccine QDENGA gets European Commission nod Ruchika Sharma10 Dec 2022 10:00 AM ISTQDENGA (TAK-003) is a dengue vaccine that is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four...
Takeda Dengue Vaccine TAK-003 gets USFDA priority review Ruchika Sharma23 Nov 2022 5:00 PM ISTTakeda's tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic "backbone"...
Takeda, Zedira and Dr Falk Pharma ink pact to develop Celiac Disease therapy Ruchika Sharma24 Oct 2022 1:00 PM ISTTAK-227 is a selective, oral small molecule designed to inhibit tissue transglutaminase (TG2), an enzyme that generates immunogenic gluten peptide...
Takeda gets positive CHMP opinion recommending nod of Dengue Vaccine in EU, Dengue-endemic countries Ruchika Sharma16 Oct 2022 12:00 PM ISTJapan: Takeda has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Takeda dengue vaccine TAK-003 provides continued protection against dengue fever through 4.5 years in trial Roshni Dhar11 Jun 2022 5:06 PM ISTTakeda has announced that its dengue vaccine candidate, TAK-003, prevented 84% of hospitalized dengue cases and 61% of symptomatic cases, with no...
Health Bulletin 11/6/2022 Roshni Dhar11 Jun 2022 4:27 PM ISTHere are the top health stories for the day:NMC orders crackdown on referral fee, commissions, and online procurement of patients ...
Takeda Dengue vaccine TAK-003 provides continued protection against dengue fever through 4.5 years in trial Ruchika Sharma11 Jun 2022 10:00 AM ISTNew Delhi: Takeda has announced that its dengue vaccine candidate, TAK-003, prevented 84% of hospitalized dengue cases and 61% of...
Moderna gets back Spikevax marketing rights in Japan Ruchika Sharma1 Jun 2022 10:00 AM ISTIn Japan, Spikevax is indicated for the prevention of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Novavax partner gets Japenese nod for Nuvaxovid Ruchika Sharma19 April 2022 5:18 PM ISTNovavax licensed and transferred its manufacturing technologies and is supplying the Matrix-M adjuvant to enable Takeda to manufacture the vaccine at...
Takeda Livtencity gets USFDA nod for treatment of post-transplant cytomegalovirus infection Ruchika Sharma24 Nov 2021 1:20 PM ISTLIVTENCITY is a new molecular entity which targets CMV at pUL97, resulting in inhibition of viral DNA replication, encapsidation and nuclear egress.
